RxDoctor Payments Data

Alexander Villacastin

Adult Health · Citrus Springs, FLNPI 1174720619

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,638 of the $15,140 with a category attached, or 83.5%. 41 manufacturers reported payments, led by AbbVie at 30.2% of the total. Reporting peaked in 2022 at $5,470 and has fallen 65.3% since, to $1,898 in 2025. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,140in general payments, 2019–2025

Across 547 payments — averaging $27.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Pfizer$923
  • Boehringer Ingelheim$697
  • Johnson & Johnson$682
  • plus $5K from 35 others

What the payments were for

  • Speaking & faculty fees$2,50017%
  • Food & beverage$12,63883%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,140 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol184$237,001
OzempicSemaglutide114$204,556
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$127,136
JardianceEmpagliflozin93$98,954
TrulicityDulaglutide59$96,983
EliquisApixaban90$82,510
MounjaroTirzepatide36$41,074
MyrbetriqMirabegron37$39,040
XifaxanRifaximin13$38,498
XareltoRivaroxaban30$37,798
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$33,855
Repatha SureclickEvolocumab37$32,333
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$31,647
LinzessLinaclotide19$26,776
RybelsusSemaglutide25$24,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,657$281,624234 claims
Novo NordiskOzempic, Rybelsus$1,649$229,552139 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$459$151,683126 claims
Lilly USA, LLCTrulicity, Mounjaro$529$138,05795 claims
PfizerEliquis, Nurtec Odt$923$106,909102 claims
Boehringer IngelheimJardiance$697$98,95493 claims
Astellas Pharma US IncMyrbetriq$231$39,04037 claims
Johnson & JohnsonXarelto$682$37,79830 claims
AbbVieLinzess$4,579$26,77619 claims
AmgenProlia$431$22,06913 claims
NovartisEntresto$272$15,64617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.

Other adult health in Citrus Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →